The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 5, 2008, Pages 409-412

  Muslimani, Alaa A ^a   Farag, Hany L ^a   Francis, Smitha ^a   Spiro, Timothy P ^b   Chaudhry, Asif A ^b   Chan, Vincent C ^c   Taylor, Harris C ^c   Daw, Hamed A ^b  

^a FAIRVIEW HOSPITAL   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18 F fluorodeoxyglucose positron emission tomography; Bone marrow involvement; Non Hodgkin lymphomas

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CANCER; CANCER STAGING; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BONE MARROW; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 55249117290     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318168d90b     Document Type: Article

References (22)

1. Bartl R, Frisch B, Burkhardt R, et al. Lymphoproliferations in the bone marrow: identification and evolution; classification and staging. J Clin Pathol. 1984;37:233-254.
2. Shields AF, Porter BA, Churchley S, et al. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. J Clin Oncol. 1987;5:225-230.
3. Isasi CR, Lu P, Blaufox MD. A metaanalysis of (18)F-2-deoxy-2-fluoro- D-glucose positron emission tomography in staging and restaging of patients with lymphoma. Cancer. 2005;104:1066-1074.
4. McKenna RW, Hernandez JA. Bone marrow in malignant lymphoma. Haematol Oncol Clin North Am. 1988;2:617-635.
5. Conlan MG, Bast M, Armitage JO, et al. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska lymphoma study group. J Clin Oncol. 1990;8:1163-1172.
6. Bennett JM, Cain KC, Glick JH, et al. The significance of bone marrow involvement in NHL: the Eastern Cooperative Oncology Group experience. J Clin Oncol. 1986;4:1462-1469.
7. McKenna RW, Bloomfield CD, Brunning RD. Nodular lymphoma: bone marrow and blood manifestations. Cancer. 1975;36:428-440.
8. Foucar K, McKenna RW, Frizzera G, et al. Bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. Cancer. 1982;49:888-897.
9. Brunning RD, Bloomfield CD, McKenna RW, et al. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic disease. Ann Intern Med. 1975;82:365-366.
10. Juneja SK, Wolf MM, Cooper IA. Value of bilateral bone marrow biopsy specimens in NHL. J Clin Pathol. 1990;43:630-632.
11. Warburg O. The Metabolism of Tumors. New York, NY: Richard R Smith Inc.; 1931:129-169.
12. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18] fluoro-2-deoxy-D-glucose: correlation with CT. Radiology. 1994;190:111-116.
13. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18-F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 1999;20:13-20.
14. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med. 1991;32:686-691.
15. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in NHL: a PET study. J Nucl Med. 1991;32:1211-1214.
16. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison of proliferative activity. J Nucl Med. 1992;33:325-329.
17. Lapela M, Leskinen S, Minn HR, et al. Increased glucose metabolism in untreated NHL: a study with PET and fluorine-18-fluorodeoxyglucose. Blood. 1995;86:3522-3527.
18. Goldberg MA, Lee MJ, Fischman AJ, et al. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. Radiographics. 1993;13:1047-1062.
19. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875-3876.
20. Pakos E, Fotopoulos A, Ioannidis J. 18-F-FDC PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46:958-963.
21. Moog F, Bangetter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603-609.
22. Civigi C. Imaging: staging and evaluation of lymphoma using nuclear medicine. Semin Oncol. 2005;9:S11-S18.